donepezil has been researched along with Delirium of Mixed Origin in 21 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Excerpt | Relevance | Reference |
---|---|---|
"To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair." | 9.15 | Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. ( Appleton, P; Davis, RB; Marcantonio, ER; Palihnich, K, 2011) |
"This was a pilot, phase 2a study to assess methodological feasibility and the safety and efficacy of donepezil in preventing postoperative delirium after elective total hip replacement surgery in older people without pre-existing dementia." | 9.12 | A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. ( Blanchard, MR; Blizard, R; Bruce, A; Garlick, N; Ndhlovu, PN; Raven, PR; Ritchie, CW; Sampson, EL; Vallance, A; Watts, J, 2007) |
"This pilot study was unable to demonstrate a benefit for donepezil in preventing or treating delirium in a relatively young and cognitively-intact group of elderly patients undergoing elective orthopedic surgery." | 9.11 | Donepezil in the prevention and treatment of post-surgical delirium. ( Fingeroth, R; Garb, JL; Krushell, R; Laki, A; Liptzin, B, 2005) |
"We utilized the Medical Information Mart for Intensive Care III (MIMIC-III) database to determine whether pre-hospital donepezil use was associated with improved outcomes during critical illness in dementia patients." | 8.31 | Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. ( Lee, S; Lieberman, OJ; Zabinski, J, 2023) |
"A severe intractable delirium caused by the basal forebrain vascular lesion and its dramatic recovery after donepezil administration were reported." | 7.72 | Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil. ( Higashima, M; Kidani, T; Kobayashi, K; Koshino, Y; Mutou, K; Tachibana, O; Yamashita, J, 2004) |
"When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 5.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
"Delirium is a common complication of dementia and may produce considerable morbidity." | 5.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
"To determine whether donepezil hydrochloride can reduce the prevalence and severity of delirium in older adults undergoing hip fracture repair." | 5.15 | Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. ( Appleton, P; Davis, RB; Marcantonio, ER; Palihnich, K, 2011) |
"This was a pilot, phase 2a study to assess methodological feasibility and the safety and efficacy of donepezil in preventing postoperative delirium after elective total hip replacement surgery in older people without pre-existing dementia." | 5.12 | A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. ( Blanchard, MR; Blizard, R; Bruce, A; Garlick, N; Ndhlovu, PN; Raven, PR; Ritchie, CW; Sampson, EL; Vallance, A; Watts, J, 2007) |
"This pilot study was unable to demonstrate a benefit for donepezil in preventing or treating delirium in a relatively young and cognitively-intact group of elderly patients undergoing elective orthopedic surgery." | 5.11 | Donepezil in the prevention and treatment of post-surgical delirium. ( Fingeroth, R; Garb, JL; Krushell, R; Laki, A; Liptzin, B, 2005) |
"There is currently no evidence from controlled trials that donepezil is effective in the treatment of delirium." | 4.84 | Cholinesterase inhibitors for delirium. ( Burns, A; Karim, S; Overshott, R, 2008) |
"We utilized the Medical Information Mart for Intensive Care III (MIMIC-III) database to determine whether pre-hospital donepezil use was associated with improved outcomes during critical illness in dementia patients." | 4.31 | Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium. ( Lee, S; Lieberman, OJ; Zabinski, J, 2023) |
"We present a case of delirium due to amitriptyline overdose, which resolved rapidly following initiation of the cholinesterase inhibitor donepezil." | 3.72 | Donepezil for anticholinergic drug intoxication: a case report. ( Aksu, H; Elbi, H; Noyan, MA, 2003) |
"A severe intractable delirium caused by the basal forebrain vascular lesion and its dramatic recovery after donepezil administration were reported." | 3.72 | Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil. ( Higashima, M; Kidani, T; Kobayashi, K; Koshino, Y; Mutou, K; Tachibana, O; Yamashita, J, 2004) |
"Delirium is very common in the elderly." | 2.44 | [Delirium]. ( Derouesné, C; Lacomblez, L, 2007) |
"Delirium is a common mental disorder with serious adverse outcomes in hospitalised patients." | 2.44 | Interventions for preventing delirium in hospitalised patients. ( Britton, AM; Holmes, J; Siddiqi, N; Stockdale, R, 2007) |
"When donepezil was re-prescribed, the delirium resolved and the patient's mental state stabilized." | 1.38 | Withdrawal syndrome after donepezil cessation in a patient with dementia. ( Bidzan, L; Bidzan, M, 2012) |
"However, interictal delirium is uncommon in absence of risk factors." | 1.38 | Delayed onset and prolonged interictal delirium following electroconvulsive therapy. ( Praharaj, SK; Selvaraj, AG, 2012) |
"Delirium is a common complication of dementia and may produce considerable morbidity." | 1.30 | Donepezil improves symptoms of delirium in dementia: implications for future research. ( Burke, WJ; Roccaforte, WH; Wengel, SP, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (14.29) | 18.2507 |
2000's | 9 (42.86) | 29.6817 |
2010's | 8 (38.10) | 24.3611 |
2020's | 1 (4.76) | 2.80 |
Authors | Studies |
---|---|
Lieberman, OJ | 1 |
Lee, S | 1 |
Zabinski, J | 1 |
Tung, EE | 1 |
Litin, SC | 1 |
Bundrick, JB | 1 |
Naharci, MI | 1 |
Takamiya, A | 1 |
Sawada, K | 1 |
Hirano, J | 1 |
Mimura, M | 1 |
Kishimoto, T | 1 |
Stocker, L | 1 |
Jellestad, L | 1 |
Jenewein, J | 1 |
Boettger, S | 1 |
Kinoshita, T | 1 |
Hanabusa, H | 1 |
Marcantonio, ER | 1 |
Palihnich, K | 1 |
Appleton, P | 1 |
Davis, RB | 1 |
Bidzan, L | 1 |
Bidzan, M | 1 |
Selvaraj, AG | 1 |
Praharaj, SK | 1 |
Noyan, MA | 1 |
Elbi, H | 1 |
Aksu, H | 1 |
Kobayashi, K | 1 |
Higashima, M | 1 |
Mutou, K | 1 |
Kidani, T | 1 |
Tachibana, O | 1 |
Yamashita, J | 1 |
Koshino, Y | 1 |
Liptzin, B | 1 |
Laki, A | 1 |
Garb, JL | 1 |
Fingeroth, R | 1 |
Krushell, R | 1 |
Sampson, EL | 1 |
Raven, PR | 1 |
Ndhlovu, PN | 1 |
Vallance, A | 1 |
Garlick, N | 1 |
Watts, J | 1 |
Blanchard, MR | 1 |
Bruce, A | 1 |
Blizard, R | 1 |
Ritchie, CW | 1 |
Derouesné, C | 1 |
Lacomblez, L | 1 |
Logan, CJ | 1 |
Stewart, JT | 1 |
Siddiqi, N | 1 |
Stockdale, R | 1 |
Britton, AM | 1 |
Holmes, J | 1 |
Overshott, R | 1 |
Karim, S | 1 |
Burns, A | 1 |
Kaufer, DI | 1 |
Catt, KE | 1 |
Lopez, OL | 1 |
DeKosky, ST | 1 |
Wengel, SP | 2 |
Roccaforte, WH | 2 |
Burke, WJ | 2 |
Kawashima, T | 1 |
Yamada, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period[NCT00586196] | Phase 2 | 16 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)[NCT01700816] | 40 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Low incidence of delirium.) | |||
Impact of Dexmedetomidine on Long-term Outcome in Elderly Patients After Noncardiac Surgery: 3-year Follow-up of a Randomized Controlled Trial[NCT02809937] | Phase 4 | 700 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P[NCT02558777] | 50 participants (Actual) | Interventional | 2013-10-31 | Completed | |||
The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial[NCT02200172] | Phase 2 | 60 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
Impact of Dexmedetomidine on Long-term Outcome in Elderly Patients After Noncardiac Surgery: 5-year Follow-up of a Randomized Controlled Trial[NCT03436472] | 700 participants (Actual) | Interventional | 2017-06-01 | Completed | |||
Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Measures severity of 10 delirium symptoms items (0 not present, 1 mild, 2 moderate, 3 severe) yielding a total score of 0 to 30, with 30 most severe. (NCT00586196)
Timeframe: Baseline, hospital discharge, weeks 2, 4 and 6
Intervention | units on a scale (Mean) | ||||
---|---|---|---|---|---|
Baseline | Change at Hospital Discharge | Change at Week 2 | Change at week 4 | Change at week 6 | |
Donepezil : 5 mg Each Day for 30 Days | 6.3 | 1.3 | -0.1 | -1.2 | -0.6 |
Placebo : Encapsulated Cornstarch | 8.4 | 1.6 | -2.2 | -2.0 | -2.0 |
Confusion Assessment Method (CAM)-Measure of the presence or absence of delirium. Requires 1) acute change with fluctuating course, 2) inattention, and either 3) disorganized thinking or 4) altered level of consciousness. (NCT00586196)
Timeframe: Baseline, hospital interviews, weeks 2, 4 and 6
Intervention | percentage of participants (Number) | ||||
---|---|---|---|---|---|
basline | hospital interviews | Week 2 | week 4 | week 6 | |
Donepezil : 5 mg Each Day for 30 Days | 14 | 64 | 43 | 17 | 50 |
Placebo : Encapsulated Cornstarch | 44 | 64 | 43 | 43 | 50 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | volume percentage (vol%) of red blood ce (Median) |
---|---|
Bright Light Therapy | 28.20 |
Sham Light | 26.70 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | g/dl (Median) |
---|---|
Bright Light Therapy | 9.70 |
Sham Light | 9.55 |
(NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | days (Median) |
---|---|
Bright Light Therapy | 18 |
Sham Light | 18.5 |
Monday, Wednesday, and Friday assessments will begin after beginning light therapy and include the Delirium Rating Scale-Revised-98 (DRS-98)and Memorial Delirium Assessment Scale (MDAS) (NCT01700816)
Timeframe: From hospital admission until the date of first documented delirium, assessed up to 28 days post-transplant
Intervention | Participants (Count of Participants) |
---|---|
Bright Light Therapy | 1 |
Sham Light | 0 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | thousand cells/uL (Median) |
---|---|
Bright Light Therapy | 39 |
Sham Light | 33.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | M/uL (Median) |
---|---|
Bright Light Therapy | 3.21 |
Sham Light | 2.93 |
"Monday, Wednesday, and Friday assessments of the Memorial Delirium Assessment Scale (MDAS); Patients will receive assessments after beginning light therapy until day 28 post-transplant or discharge, whichever comes first.~10 item scale Items are rated on a four-point scale from 0 (none) to 3 (severe) depending on the level of impairment, rendering a maximum possible score of 30.~A score of 13 has been recommended as a cut-off for establishing the diagnosis of delirium" (NCT01700816)
Timeframe: From first documented episode of delirium until discharge from the hospital, assessed up to 28 days post-transplant
Intervention | units on a scale (Number) |
---|---|
Bright Light Therapy | 18 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | K/uL (Median) |
---|---|
Bright Light Therapy | 2.30 |
Sham Light | 4.75 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT. (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | mg/dl (Median) | |
---|---|---|
Serum Creatinine | Blood Urea Nitrogen (BUN) | |
Bright Light Therapy | 0.66 | 9 |
Sham Light | 0.75 | 8.5 |
Lab values at latest available follow-up date per participant. These tests are performed as part of routine clinical care on patients undergoing HSCT (Hematopoietic Stem Cell Transplantation). (NCT01700816)
Timeframe: From admission to hospital to discharge, an expected average of 28 days post-transplant
Intervention | mmol/L (Median) | |||
---|---|---|---|---|
Sodium (Na) | Potassium (K) | Chloride (Cl) | Carbon Dioxide (CO2) | |
Bright Light Therapy | 139 | 3.6 | 105 | 24.9 |
Sham Light | 138.0 | 3.80 | 103.0 | 25.10 |
4 reviews available for donepezil and Delirium of Mixed Origin
Article | Year |
---|---|
Issues facing home-based medical support services.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Caregivers; Delirium; Dementia; Diagnosis, Differenti | 2010 |
[Delirium].
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Confusion; Delirium; | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Interventions for preventing delirium in hospitalised patients.
Topics: Anesthesia, Epidural; Anesthetics, Inhalation; Cytidine Diphosphate Choline; Delirium; Donepezil; Ha | 2007 |
Cholinesterase inhibitors for delirium.
Topics: Cholinesterase Inhibitors; Delirium; Donepezil; Humans; Indans; Piperidines | 2008 |
3 trials available for donepezil and Delirium of Mixed Origin
Article | Year |
---|---|
Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delirium; Donepezil; Double-Blind Method; Female | 2011 |
Donepezil in the prevention and treatment of post-surgical delirium.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Delirium; Donepezil; Double-Blind Method; Female | 2005 |
A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Delirium; Donepezil; Double-Blind Method; E | 2007 |
14 other studies available for donepezil and Delirium of Mixed Origin
Article | Year |
---|---|
Donepezil treatment is associated with improved outcomes in critically ill dementia patients via a reduction in delirium.
Topics: Cholinergic Agents; Critical Illness; Delirium; Dementia; Donepezil; Humans | 2023 |
Clinical Pearls in Geriatrics.
Topics: Acetaminophen; Aged; Aged, 80 and over; Automobile Driving; Cognition Disorders; Cognitive Dysfuncti | 2017 |
Could delirium and anti-dementia drugs effect the treatment of agitated nursing home residents with Alzheimer dementia?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Delirium; Don | 2018 |
Prolonged Post-Electroconvulsive Therapy Delirium Controlled With Donepezil.
Topics: Bipolar Disorder; Chronic Disease; Delirium; Donepezil; Electroconvulsive Therapy; Female; Humans; M | 2019 |
Challenges in the management of delirium: a case of augmentation with donepezil following inadequate response and adverse effects with risperidone.
Topics: Anticholinergic Syndrome; Antiparkinson Agents; Antipsychotic Agents; Biperiden; Burns; Cholinestera | 2015 |
Withdrawal syndrome after donepezil cessation in a patient with dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Delirium; Dementia; Donepezil; Female; Humans; Indans; | 2012 |
Delayed onset and prolonged interictal delirium following electroconvulsive therapy.
Topics: Cholinesterase Inhibitors; Delirium; Depressive Disorder; Donepezil; Electroconvulsive Therapy; Foll | 2012 |
Donepezil for anticholinergic drug intoxication: a case report.
Topics: Amitriptyline; Cholinergic Antagonists; Delirium; Donepezil; Drug Overdose; Humans; Indans; Male; Mi | 2003 |
Severe delirium due to basal forebrain vascular lesion and efficacy of donepezil.
Topics: Aged; Basal Ganglia Cerebrovascular Disease; Basal Nucleus of Meynert; Craniopharyngioma; Delirium; | 2004 |
Treatment of post-electroconvulsive therapy delirium and agitation with donepezil.
Topics: Aged; Cholinesterase Inhibitors; Delirium; Depressive Disorder, Major; Donepezil; Electroconvulsive | 2007 |
Dementia with Lewy bodies: response of delirium-like features to donepezil.
Topics: Aged; Brain; Delirium; Dementia; Donepezil; Humans; Indans; Lewy Bodies; Magnetic Resonance Imaging; | 1998 |
Donepezil improves symptoms of delirium in dementia: implications for future research.
Topics: Aged; Alcohol Withdrawal Delirium; Cholinesterase Inhibitors; Cognition Disorders; Delirium; Dementi | 1998 |
Donepezil for postoperative delirium associated with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Delirium; Donepezil; Geriatric Assessment; Humans; Indans; Male; Nootropic | 1999 |
Delirium caused by donepezil: a case study.
Topics: Aged; Alzheimer Disease; Atrophy; Cerebral Cortex; Delirium; Donepezil; Humans; Indans; Male; Nootro | 2002 |